HB 195 is a broad health professions and public health bill that primarily renames “physician assistant” to “physician associate” throughout Alaska law and updates numerous statutes to reflect that terminology. It also revises the scope of practice and regulatory framework for physician associates, including their role in telehealth prescribing, supervision, delegation of routine medical duties, board membership, death pronouncements, do-not-resuscitate orders, and participation in mental health and emergency care processes. The bill makes conforming changes across many titles of Alaska statutes so that physician associates are recognized alongside physicians, advanced practice registered nurses, pharmacists, and other licensed health care providers in a wide range of settings.
A major second component of the bill expands and clarifies pharmacist authority. HB 195 limits state regulation of collaborative practice agreements by prohibiting fees, approval requirements, and other board regulation of those agreements, while also defining pharmacist “patient care services” and allowing pharmacists to independently provide certain services for general wellness, disease prevention, and minor self-limiting conditions. The bill also updates pharmacist licensure, reciprocity, continuing education, and board powers, and it expressly authorizes pharmacists to prescribe or administer certain drugs and devices, including opioid overdose drugs, subject to training and other limits. It amends the definition of “practitioner” in controlled substances law to include pharmacists prescribing or administering controlled substances in the course of professional practice.
HB 195 also adds or reinforces opioid-related prescribing requirements across several licensing chapters. Physicians, physician associates, advanced practice registered nurses, and optometrists are required to offer an opioid overdose drug prescription in specified higher-risk situations, such as longer opioid prescriptions, higher daily morphine milligram equivalents, concurrent benzodiazepine use, or a history of overdose or substance use disorder. The bill also requires pain-management and opioid-use education in pharmacist licensure and continuing education, and it updates multiple definitions and cross-references related to opioid overdose drugs and controlled substances.
The bill’s impact on state law is extensive because it amends many separate statutes governing medical licensing, pharmacy practice, emergency medical services, mental health, advance directives, disability designations, workers’ compensation, insurance, and public health. It changes who may perform or certify certain medical acts, broadens or clarifies the legal recognition of physician associates in numerous contexts, and creates a new statutory rule limiting state regulation of collaborative practice agreements. Several provisions are delayed until January 1, 2027, and some physician-associate-related sections are conditioned on whether SB 89 becomes law, indicating the bill was drafted to coordinate with separate legislation on the same terminology change.
No committee transcripts or recorded votes were provided, so the available context does not show direct debate or roll-call support/opposition. Based on the bill’s structure, the likely sentiment is generally supportive of modernizing professional terminology, expanding access to care, and increasing pharmacist and mid-level provider flexibility, while also emphasizing opioid safety. The main points of contention suggested by the text are the bill’s restriction on state oversight of collaborative practice agreements, the expansion of pharmacist independent authority, and the breadth of statutory changes affecting multiple health professions and regulatory boards.
HB 195 makes sweeping conforming amendments across Alaska statutes to replace “physician assistant” with “physician associate” and to update the legal status, duties, and references for physician associates in licensing, telehealth, emergency care, death pronouncement, advance directives, mental health, workers’ compensation, insurance, and public health laws. It also significantly changes pharmacy law by expanding pharmacist patient-care authority, authorizing certain prescribing and administration activities, limiting regulation of collaborative practice agreements, and updating pharmacist licensure, reciprocity, and continuing education requirements. The bill adds or reinforces opioid-overdose-drug offering requirements for several prescribers and updates controlled-substance definitions and practitioner language.
No committee discussion or vote history was provided, so there is no direct recorded legislative sentiment in the materials. The bill’s text suggests a generally favorable policy direction toward modernizing professional titles, expanding access to care, and increasing pharmacist and physician-associate flexibility, while also incorporating opioid-safety measures. The absence of recorded opposition or amendments in the provided context makes it difficult to identify formal support or resistance beyond the statutory changes themselves.
The most notable potential contention is the bill’s directive that the department or a board may not require fees, approval, or other regulation of pharmacist collaborative practice agreements, which reduces oversight and may concern regulators or professional groups favoring stricter control. Another likely point of debate is the expansion of pharmacist authority to provide patient care services and prescribe or administer certain drugs, including controlled substances in limited circumstances. The broad terminology change from “physician assistant” to “physician associate,” and the bill’s many cross-cutting amendments affecting multiple health professions, could also draw attention from stakeholders concerned about scope of practice, licensing standards, and implementation timing.